Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models
Manali S Phadke, Jiannong Li, Zhihua Chen, Paulo C Rodriguez, Jessica K Mandula, Lilit Karapetyan, Peter A Forsyth, Y Ann Chen, Keiran S M Smalley · 2023
Read Differential requirements for CD4+ T cells in the efficacy of the anti-PD-1+LAG-3 and anti-PD-1+CTLA-4 combinations in melanoma flank and brain metastasis models by Manali S Phadke, Jiannong Li, Zhihua Chen, Paulo C Rodriguez, Jessica K Mandula, Lilit Karapetyan, Peter A Forsyth, Y Ann Chen, Keiran S M Smalley (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10711842.txt.
Description
Phadke and co-authors probe how two drug pairs fight melanoma, and what role CD4 T cells play in each. Both pairs block PD-1 plus a second checkpoint, either LAG-3 or CTLA-4. Both work in advanced melanoma, but whether they work the same way was unclear. The team used mouse tumors on the flank and in the brain. They profiled the tumors with single-cell sequencing, flow tests, and tissue staining.
The CTLA-4 pair drew in regulatory CD4 cells and a set of killer CD8 cells. The LAG-3 pair leaned more on help from active CD4 cells. Removing CD4 cells hurt the two pairs to different degrees. The results suggest the pairs succeed through distinct immune routes.
Catalog record
| CREATOR | Manali S Phadke, Jiannong Li, Zhihua Chen, Paulo C Rodriguez, Jessica K Mandula, Lilit Karapetyan, Peter A Forsyth, Y Ann Chen, Keiran S M Smalley |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |